menu
    • menu
    [{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","graph1":"Ophthalmology","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"intravitreal implant","sponsorNew":"EyePoint Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","graph1":"Ophthalmology","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Intravitreal Implant","sponsorNew":"EyePoint Pharmaceuticals \/ SWK Holdings Corporation","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint Pharmaceuticals \/ SWK Holdings Corporation"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","graph1":"Ophthalmology","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Intravitreal Implant","sponsorNew":"EyePoint Pharmaceuticals \/ Ocumension Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint Pharmaceuticals \/ Ocumension Therapeutics"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Phospholipase A2","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Alimera Sciences \/ Not Applicable"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"EyePoint Pharmaceuticals \/ OcuMension Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint Pharmaceuticals \/ OcuMension Therapeutics"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"PLA2","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"SIFI","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alimera Sciences \/ SIFI","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sciences \/ SIFI"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Horus Pharma","sponsor":"Alimera Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Horus Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Horus Pharma \/ Alimera Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Horus Pharma \/ Alimera Sciences"},{"orgOrder":0,"company":"EyePoint Pharmaceuticals","sponsor":"Alimera Sciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"EyePoint Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.080000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"EyePoint Pharmaceuticals \/ Alimera Sciences","highestDevelopmentStatusID":"12","companyTruncated":"EyePoint Pharmaceuticals \/ Alimera Sciences"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Alimera Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Alimera Sciences \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Alimera Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Alimera Sciences","amount2":0.38,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.38,"dosageForm":"Implant","sponsorNew":"Alimera Sciences \/ ANI Pharmaceuticals Inc","highestDevelopmentStatusID":"12","companyTruncated":"Alimera Sciences \/ ANI Pharmaceuticals Inc"},{"orgOrder":0,"company":"Eclipse Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Eclipse Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Eclipse Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Eclipse Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alimera Sciences","amount2":0.38,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alimera Sciences \/ ANI Pharmaceuticals Inc","highestDevelopmentStatusID":"14","companyTruncated":"Alimera Sciences \/ ANI Pharmaceuticals Inc"},{"orgOrder":0,"company":"Alimera Sciences","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Fluocinolone Acetonide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Alimera Sciences","amount2":0.38,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Alimera Sciences \/ ANI Pharmaceuticals Inc","highestDevelopmentStatusID":"14","companyTruncated":"Alimera Sciences \/ ANI Pharmaceuticals Inc"}]

    Find Clinical Drug Pipeline Developments & Deals for Fluocinolone Acetonide

    Menu

    Fluocinolone Acetonide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alimera Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Alimera Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : ANI Pharmaceuticals Inc

                            Deal Size : $381.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences

                            Details : Upon acquisition ANI will inherit Iluvien (fluocinolone acetonide), a drug used to treat diabetic macular oedema & recurrent non-infectious posterior uveitis in the US, Europe and Middle East.

                            Brand Name : Iluvien

                            Molecule Type : Small molecule

                            Upfront Cash : $381.0 million

                            September 16, 2024

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : ANI Pharmaceuticals Inc

                            Deal Size : $381.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alimera Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Alimera Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : ANI Pharmaceuticals Inc

                            Deal Size : $381.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger

                            Details : Upon acquisition ANI will inherit Iluvien (fluocinolone acetonide), a drug used to treat diabetic macular oedema & recurrent non-infectious posterior uveitis in the US, Europe and Middle East.

                            Brand Name : Iluvien

                            Molecule Type : Small molecule

                            Upfront Cash : $381.0 million

                            September 11, 2024

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : ANI Pharmaceuticals Inc

                            Deal Size : $381.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eclipse Life Sciences

                            Country arrow
                            2024 ACI Convention
                            Not Confirmed

                            Eclipse Life Sciences

                            Country arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eclipse Initiates Phase 2 Study for Steroid Implant in Diabetic Macular Edema

                            Details : EC-104 (fluocinolone acetonide) extended release, a novel intravitreal corticosteroid implant is being investigated for the treatment of diabetic macular edema (DME).

                            Brand Name : EC-104

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 12, 2024

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alimera Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Alimera Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : ANI Pharmaceuticals Inc

                            Deal Size : $381.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            ANI Pharmaceuticals Expands Rare Disease Business by Acquiring Alimera Sciences

                            Details : Upon acquisition ANI will inherit Iluvien (fluocinolone acetonide), a drug used to treat diabetic macular oedema & recurrent non-infectious posterior uveitis in the US, Europe and Middle East.

                            Brand Name : Iluvien

                            Molecule Type : Small molecule

                            Upfront Cash : $381.0 million

                            June 24, 2024

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : ANI Pharmaceuticals Inc

                            Deal Size : $381.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Alimera Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Alimera Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alimera Completes Recruitment for the Synchronicity Study

                            Details : YUTIQ (fluocinolone acetonide) intravitreal implant 0.18mg is being evaluated in phase 4 clinical trials for the treatment of chronic non-infectious uveitis and related intraocular inflammation.

                            Brand Name : Yutiq

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 04, 2024

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Alimera Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Alimera Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alimera Completes Recruitment for its Landmark NEW DAY Study

                            Details : The product ILUVIEN (fluocinolone acetonide) is a sustained release intravitreal implant injected into the back of the eye. ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to av...

                            Brand Name : Iluvien

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 24, 2023

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            EyePoint Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            EyePoint Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Alimera Sciences

                            Deal Size : $82.5 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royal...

                            Details : Through the divestment, Alimera will receive global rights to YUTIQ outside of China, Hong Kong, Taiwan, Macau and Southeast Asia. YUTIQ® (fluocinolone acetonide) is indicated for the treatment of chronic, non-infectious uveitis affecting the posterior ...

                            Brand Name : Yutiq

                            Molecule Type : Small molecule

                            Upfront Cash : $75.0 million

                            May 18, 2023

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Alimera Sciences

                            Deal Size : $82.5 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Horus Pharma

                            France arrow
                            2024 ACI Convention
                            Not Confirmed

                            Horus Pharma

                            France arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Alimera Sciences

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN®...

                            Details : Under the agreement, Alimera and Horus have agreed to increase the commercialization efforts for ILUVIEN (fluocinolone acetonide) for both diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in Euro...

                            Brand Name : Iluvien

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 03, 2023

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Alimera Sciences

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Alimera Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Alimera Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN®

                            Details : Iluvien (fluocinolone acetonide intravitreal implant) is designed to release sub-microgram levels of fluocinolone acetonide, a corticosteroid, for 36 months, to reduce the recurrence of disease, enabling patients to maintain vision longer with fewer inje...

                            Brand Name : Iluvien

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 22, 2023

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Alimera Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Alimera Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Paladin Phase 4 Study Confirms ILUVIEN® Patients' Reduced Need for Multiple Treatments

                            Details : PALADIN phase 4 data demonstrate ILUVIEN (fluocinolone acetonide) patients experienced on average an increase in visual acuity, a significant decrease in retinal thickness and a predictable and manageable safety profile over 36 months.

                            Brand Name : Iluvien

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 06, 2022

                            Lead Product(s) : Fluocinolone Acetonide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth